PMA device
Bard Lifestent Vascular Stent System
Bard Peripheral Vascular, Inc. · Stent, Superficial Femoral Artery (NIP, Class III) · First FDA decision Sep 16, 2011, newest Aug 31, 2016Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
10
Naming "Bard Lifestent"
MAUDE reports
1
Brand "Bard Lifestent", since 2015
PubMed studies
1
Mentioning "Bard Lifestent"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Bard Lifestent Vascular Stent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- BARD LIFESTENT VASCULAR STENT SYSTEMPMA supplement
P070014-S051 · Decided Aug 31, 2016 · 61 days after receipt · Normal 180 Day Track No User Fee
Device type: STENT, SUPERFICIAL FEMORAL ARTERY (NIP) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Bard Lifestent", any status and sponsor, newest update first.
- Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial LesionsStatus unknown
Medical University of ViennaAcademic, hospital or other
NCT03097679 · 86 participants · Start Oct 1, 2015 · Primary completion Jul 31, 2019
Device: Pulsar Stent; LifeStent Flexstar Vascular Stent · For: Stent Restenosis; Intimal Hyperplasia
Sites: Vienna, Austria
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Bard Lifestent", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code NIP
9,363 reports: 4,911 malfunction, 4,303 injury, 147 death
Newest reports for this brand
BARD PERIPHERAL VASCULAR, INC.
MW5152867 · Received Mar 14, 2024 · Event dated Mar 1, 2024
Device type: Stent, Superficial Femoral Artery (NIP)
Patient problem as coded: Insufficient Information
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Bard Lifestent"[tiab]. The summary above synthesizes these.
- The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease.
Bertges DJ, Eldrup-Jorgensen J, Eskandari MK, et al. · J Vasc Surg · 2023Multicenter Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code NIP.
- GORE VIABAHN EndoprosthesisW. L. Gore & Associates, Inc. · PMA 2022
- Supera Peripheral Stent SystemAbbott Vascular (Idef Technologies Inc) · PMA 2025
- LifeStent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2023
- Everflex Self-Expanding Peripheral Stent System (Everflex)Medtronic Vascular, Inc. · PMA 2025
- Innova Vascular Self-Expanding Stent SystemBoston Scientific Corporation · PMA 2021
- BioMimics 3D Vascular Stent SystemVeryan Medical, Ltd. · PMA 2025
- Astron Pulsar and Pulsar-18 Stent SystemsBiotronik AG · PMA 2018
- Misago Peripheral Self-Expanding Stent SystemTerumo Medical Corporation · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.